Synovus Financial Corp acquired a new position in shares of Bioverativ Inc (NASDAQ:BIVV) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 27,336 shares of the biotechnology company’s stock, valued at approximately $1,556,000.

Several other large investors have also recently made changes to their positions in BIVV. Advisors Asset Management Inc. purchased a new stake in shares of Bioverativ during the third quarter worth $137,000. TCI Wealth Advisors Inc. purchased a new stake in shares of Bioverativ during the third quarter worth $186,000. Canada Pension Plan Investment Board purchased a new stake in shares of Bioverativ during the third quarter worth $194,000. ACG Wealth purchased a new stake in shares of Bioverativ during the third quarter worth $205,000. Finally, Pinnacle Associates Ltd. purchased a new stake in shares of Bioverativ during the third quarter worth $217,000. Institutional investors and hedge funds own 95.23% of the company’s stock.

Bioverativ Inc (NASDAQ BIVV) opened at $50.68 on Thursday. Bioverativ Inc has a 1-year low of $40.00 and a 1-year high of $64.41.

Bioverativ (NASDAQ:BIVV) last posted its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million for the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. Bioverativ’s revenue for the quarter was up 27.2% on a year-over-year basis. equities analysts expect that Bioverativ Inc will post 2.45 EPS for the current year.

BIVV has been the subject of several recent research reports. Jefferies Group reiterated a “buy” rating and set a $70.00 price objective (up from $67.00) on shares of Bioverativ in a report on Wednesday, August 9th. Zacks Investment Research lowered Bioverativ from a “strong-buy” rating to a “sell” rating in a report on Wednesday, August 9th. Evercore ISI initiated coverage on Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price objective for the company. Royal Bank Of Canada initiated coverage on Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price objective for the company. Finally, Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $60.93.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/07/synovus-financial-corp-acquires-new-holdings-in-bioverativ-inc-bivv.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.